Publications by authors named "Philip C Lackey"
Article Synopsis
- Fostemsavir is a new drug used alongside other treatments for adults with multidrug-resistant HIV-1, focusing on its real-world effects in the OPERA cohort.
- The study analyzed immunological (CD4 T-cell counts) and virological (viral load) responses in participants starting fostemsavir, categorizing results based on their initial viral load and CD4 count.
- Results showed that while most individuals with suppressed viral loads maintained their status, those with low CD4 counts had notable improvements in immune response with fostemsavir, despite limited virological success in those who were viraemic.
BMC Infect Dis
February 2023
Article Synopsis
- - The study compared clinical outcomes between heavily treatment-experienced (HTE) and non-HTE people living with HIV (PLWH), focusing on their ART regimens and resistance to treatments over a median follow-up of 28 months.
- - Results indicated that HTE PLWH had lower chances of achieving undetectable viral loads and maintaining adequate CD4 cell counts compared to non-HTE PLWH, and they were also more likely to need changes in their treatment regimens.
- - Both groups experienced non-AIDS defining morbidities, with a higher prevalence in HTE PLWH (45%) versus non-HTE (35%), though serious morbidities and deaths were relatively rare.
Open Forum Infect Dis
August 2021
Article Synopsis
- A study investigated treatment outcomes for ART-naive people living with HIV (PLWH) who began antiretroviral therapy with high viral loads (≥100,000 copies/mL).
- The research, conducted using data from the OPERA database, focused on the effectiveness of different ART regimens, including dolutegravir (DTG), elvitegravir (EVG), raltegravir (RAL), and darunavir (DRV), over a median follow-up of 18.1 months.
- Results indicated that those starting on DTG had a lower virologic failure rate (9.2%) compared to EVG (13.2%), RAL (18.4
Infect Dis Ther
March 2020
Article Synopsis
- The study compares the clinical effectiveness of four antiretroviral therapy (ART) agents—Dolutegravir (DTG), Elvitegravir (EVG), Raltegravir (RAL), and Darunavir (DRV)—in preventing virologic failure among HIV-positive individuals.
- The analysis included 4049 ART-naïve patients and found that those starting on DTG had significantly higher rates of viral suppression compared to those on RAL and DRV, with rates of 78.7% for DTG versus only 51.9% and 48.6% for RAL and DRV, respectively.
- This indicates that DTG is more effective in achieving viral suppression and has lower associated
